STAAR lenses granted NTIOL status

Article

The Afinity Collamer aspheric single piece Intraocular Lens (IOL) Model CC4204A and the Elastimide Silicone aspheric IOL Model AQ2015A, both manufactured and marketed by STAAR Surgical, have been designated New Technology IOLs (NTIOLs) by the US Centers for Medicare and Medicaid.

The Afinity Collamer aspheric single piece Intraocular Lens (IOL) Model CC4204A and the Elastimide Silicone aspheric IOL Model AQ2015A, both manufactured and marketed by STAAR Surgical, have been designated New Technology IOLs (NTIOLs) by the US Centers for Medicare and Medicaid. STAAR also already has NTIOL status for the Collamer aspheric three-piece IOL.

NTIOL status, granted if an IOL is able to demonstrate that it provides new clinical benefits, enhances access to the latest IOL technologies to beneficiaries of the Medicare/Medicaid programmes in the US by conferring an additional reimbursement of $50 for each NTIOL provided to these beneficiaries in an Ambulatory Surgical Center (ASC).

The Afinity Collamer single piece lens, which can be implanted through a 2.2 mm incision with the nanoPOINT Injector System (STAAR Surgical), and the Elastimide Silicone lens belong to the Reduced Spherical Aberrations subset of NTIOLs. The additional reimbursement for which these lenses are now eligible will run until 26 February 2011.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.